Breakthrough Device Designation for JointMedica’s Polymotion Hip Resurfacing

Exactech announced that FDA granted a Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System.

Exactech, a minority shareholder of JointMedica, is collaborating to deliver the next generation of hip resurfacing to the global market, and holds exclusive global distribution rights to the product.

The Polymotion hip is designed to offer the biomechanical benefits of hip resurfacing while eliminating metal-on-metal articulating surfaces.

“Through this deep collaboration, Exactech and JointMedica are well-positioned to bring the Polymotion Hip Resurfacing System to the global market,” said Jeff Binder, CEO and Chairman of the Board of Exactech. “Polymotion will complement Exactech’s Alteon® hip arthroplasty portfolio, comprised of substantial advancements in design and materials to time-tested solutions.”

Source: Exactech